We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
What Break Through Means to Us
Surface Oncology is driven to deliver transformational outcomes for people with cancer who have no effective treatment options. We push ourselves to break through across all dimensions of our work by:
Setting a high bar for potential patient impact at every stage of development
Focusing on interrogating the most meaningful targets with proven technologies
Leveraging multiple platforms to make fast decisions to benefit our overall portfolio
Fostering an energetic and highly collaborative culture that emphasizes collective learning
Our leaders and advisors drive the bold pursuit of transformative cancer care.
Scientific Advisory Board
Board of Directors
Pushing Further with Partners
To break through the current boundaries of medical science, collaborations are a crucial part of our strategy. In January 2016, Surface entered into a strategic collaboration with Novartis to advance our next-generation cancer therapies.
Under the agreement, Novartis currently has an exclusive worldwide license to our fully human CD73 antibody, NZV930 (formerly SRF373). Surface has received an upfront payment of $70 million from Novartis and is entitled to potential milestone payment upon the achievement of specified development and sales milestones of $525 million as well as tiered royalties.
Are you interested in partnering with Surface? Please contact us at email@example.com.